Compounded Sema Injectable denied for missing prior authorization by Cigna?

Cigna's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Compounded Semaglutide for Missing Prior Authorization

For compounded semaglutide, a "prior-auth-required" denial adds a procedural layer on top of the substantive coverage challenges these products already face. Cigna requires prior authorization for drugs in this therapeutic class, meaning the prescriber or patient must request and receive written approval before the prescription is dispensed or reimbursed. If that step was skipped, or if the authorization request was submitted but denied (triggering this notice), the denial reflects either a process gap or an underlying coverage determination that must now be appealed.

## Why This Is Appealable

If prior authorization was never requested, the appeal must argue for retroactive coverage by demonstrating medical necessity and, if the product was dispensed during a known shortage, that the urgency of the clinical situation justified proceeding. If prior authorization was requested and denied, the appeal contests the denial on medical-necessity, shortage-access, or formulary-exception grounds. For compounded semaglutide, the prior-auth denial often masks a deeper coverage exclusion — so the appeal should address both the procedural prior-auth basis and the underlying substantive basis (shortage access, medical necessity, or formulary exception) in a single letter.

## The Federal Appeal Framework

• Internal appeal: File under ERISA Section 503 (employer plans) or ACA Section 2719 (individual/marketplace plans) within the deadline printed on the denial notice. For pre-service prior-auth requests, Cigna must respond within 30 days; for urgent requests, within 72 hours (or 24 hours if expedited).
• Peer-to-peer review: Prescribers may request a peer-to-peer call with Cigna's medical director — this is often the fastest path to overturning a prior-auth denial when the prescriber can speak directly to clinical necessity.
• External review: After exhausting internal appeals, you generally have approximately four months to request independent external review under ACA Section 2719. The external reviewer applies clinical standards, not Cigna's internal prior-auth criteria.
• Expedited review: Request if delay poses imminent clinical harm.

## Documentation to Gather

• Diagnosis and severity: Chart notes confirming the clinical diagnosis, severity indicators, relevant lab or measurement history drawn from the chart, and functional impact.
• Prior treatment history with outcomes: A complete chronological list of pharmacological treatments tried before semaglutide was prescribed — including dates, durations, and documented outcomes or reasons for stopping — demonstrating that the patient has met any step-therapy requirements in Cigna's prior-auth criteria.
• FDA shortage documentation (if applicable): If the branded FDA-approved product was unavailable at the time of prescribing, the current FDA drug shortage database entry for that product.
• Formulary exception basis: If the branded product is excluded or has prohibitive cost-sharing under this plan, document that.
• Prescriber medical-necessity letter: A structured letter addressing each criterion in Cigna's prior-authorization form for GLP-1 agents, with specific chart citations for each — and, separately, addressing why compounded access was necessary.
• Compounding pharmacy documentation: Accreditation status (PCAB or state board), if available.

## Criteria-Mapping Structure

Obtain Cigna's prior-authorization criteria for GLP-1 receptor agonists (available on Cigna's provider portal). Map every criterion to a chart document:

| Cigna Prior-Auth Criterion | Chart Evidence | |---|---| | Qualifying diagnosis confirmed | Diagnosis documentation and chart notes | | Required prior therapies tried/failed | Medication history with dates and outcomes | | Prescriber type or specialty | Treating clinician's credentials | | Monitoring plan on file | Treatment and follow-up plan in chart | | Reason branded product unavailable | FDA shortage record or formulary exclusion documentation |

If the denial letter does not specify which prior-auth criteria were unmet, Cigna is required under ERISA to provide this information upon request — ask for it in writing before or alongside your appeal, as it ensures the appeal is targeted at the actual basis for denial.